Pharmaceuticals Global On demand · 24-48h

Global Pharmaceutical Testing Market Strategic Research Report

Global Pharmaceutical Testing Market Strategic Research Repo…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Pharmaceutical Testing Market
$7.38B2025
5.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Raw Material Testing, Microbiological Testing, Drug Packaging Material Testing, Macromolecule Drug Biological Analysis and Testing, GMP Public System and Equipment Validation Testing, Pharmacovigilance, Other

By Application: CRO, CMO and CDMO, Finished Drugs and Environment

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Eurofins, WuXi AppTec, Pace Analytical Services, Catalent, LabCorp (Covance), PPD, Element (Exova), ALS Pharmaceutical, Intertek Group, SGS, Boston Analytical, DYNALABS, CTI, Weipu, PONY Medicine, WuXi Biologics, Standard Group, ICAS, APTBIO, Saifu Lab, GBTc, Kerbio, Assure, NIFDC, Frontage, Pharmaron

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 171 pages
Market size 2025
$7.38B
Billion USD
Forecast CAGR
5.4%
2025-2032
Forecast 2032
$10.7B
Projected
リージョン
5
Asia Pacific · Latin America · MEA · Europe · North America

概観

Scope of the Report

The global Pharmaceutical Testing market size is predicted to grow from US$ 7,384 million in 2025 to US$ 10,610 million in 2032; it is expected to grow at a CAGR of 5.4% from 2026 to 2032.

There are many testing items for pharmaceutical testing, including drug quality testing, drug ingredient testing, drug heavy metal testing, drug adverse reaction testing, drug sealing testing, biological drug testing, drug appearance testing, drug routine testing, drug physical and chemical testing, drug safety testing and drug defect testing, etc. The purpose of pharmaceutical testing is to prevent substandard drugs from entering the market and ensure the safety of drugs.

China Pharmaceutical Testing core manufacturers are WuXi AppTec、CTI、Weipu、PONY Medicine、SGS、WuXi Biologics and etc, the top five manufacturers account for about 14% of the Chinese share. Wuxi AppTec has the largest market, with a presence in more than 30 countries worldwide.. In terms of product type, Drug Packaging Material Testing is the largest segment with a share of about 27%. And in terms of application, Finished Drugs and Environment is the largest downstream segment with a share of 38%.

This report presents a comprehensive overview of the global Pharmaceutical Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Raw Material Testing
  • Microbiological Testing
  • Drug Packaging Material Testing
  • Macromolecule Drug Biological Analysis and Testing
  • GMP Public System and Equipment Validation Testing
  • Pharmacovigilance
  • Other

Segment by players, this report covers

  • Eurofins
  • WuXi AppTec
  • Pace Analytical Services
  • Catalent
  • LabCorp (Covance)
  • PPD
  • Element (Exova)
  • ALS Pharmaceutical
  • Intertek Group
  • SGS
  • Boston Analytical
  • DYNALABS
  • CTI
  • Weipu
  • PONY Medicine
  • WuXi Biologics
  • Standard Group
  • ICAS
  • APTBIO
  • Saifu Lab
  • GBTc
  • Kerbio
  • Assure
  • NIFDC
  • Frontage
  • Pharmaron

Segment by Application

  • CRO
  • CMO and CDMO
  • Finished Drugs and Environment

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pharmaceutical Testing market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in CRO, CMO and CDMO, Finished Drugs and Environment evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Pharmaceutical Testing Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$7.38B
2025
Forecast
$10.7B
2032
CAGR
5.4%
2025–2032
リージョン
5
global
Key companies
EurofinsWuXi AppTecPace Analytical ServicesCatalentLabCorp (Covance)PPDElement (Exova)ALS Pharmaceutical
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Raw Material TestingMicrobiological TestingDrug Packaging Material TestingMacromolecule Drug Biological Analysis and TestingGMP Public System and Equipment Validation TestingPharmacovigilanceOther
By Application
CROCMO and CDMOFinished Drugs and Environment

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Raw Material Testing
  • 3.1.3 Microbiological Testing
  • 3.1.4 Drug Packaging Material Testing
  • 3.1.5 Macromolecule Drug Biological Analysis and Testing
  • 3.1.6 GMP Public System and Equipment Validation Testing
  • 3.1.7 Pharmacovigilance
  • 3.1.8 Other
  • 3.1.9 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 CRO
  • 4.1.3 CMO and CDMO
  • 4.1.4 Finished Drugs and Environment
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Eurofins
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 WuXi AppTec
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Pace Analytical Services
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Catalent
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 LabCorp (Covance)
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 PPD
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Element (Exova)
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 ALS Pharmaceutical
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Intertek Group
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 SGS
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Boston Analytical
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 DYNALABS
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 CTI
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Weipu
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 PONY Medicine
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 WuXi Biologics
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Standard Group
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 ICAS
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 APTBIO
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Saifu Lab
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 GBTc
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 Kerbio
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Assure
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 NIFDC
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 Frontage
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Pharmaron
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Pharmaceutical Testing market?
The global Pharmaceutical Testing market is estimated at US$ 7.38 billion in 2025 (base year) and is projected to reach US$ 10.61 billion by 2032.
What is the forecast CAGR for the Pharmaceutical Testing market?
The market is expected to grow at a CAGR of 5.4% from 2026 to 2032, expanding from US$ 7.38 billion in 2025 to US$ 10.61 billion in 2032, roughly 1.4 times its base-year value.
What is Pharmaceutical Testing?
There are many testing items for pharmaceutical testing, including drug quality testing, drug ingredient testing, drug heavy metal testing, drug adverse reaction testing, drug sealing testing, biological drug testing, drug appearance testing, drug routine testing, drug physical and chemical testing, drug safety testing and drug defect testing, etc. The purpose of pharmaceutical testing is to prevent substandard drugs from entering the market and ensure the safety of drugs.
What are the main segments of the Pharmaceutical Testing market by type?
By type, the market is segmented into Raw Material Testing, Microbiological Testing, Drug Packaging Material Testing, Macromolecule Drug Biological Analysis and Testing, GMP Public System and Equipment Validation Testing, Pharmacovigilance and Other.
Which applications drive demand in the Pharmaceutical Testing market?
Key applications covered include CRO, CMO and CDMO and Finished Drugs and Environment.
Who are the key players in the Pharmaceutical Testing market?
Key players profiled include Eurofins, WuXi AppTec, Pace Analytical Services, Catalent, LabCorp (Covance), PPD, Element (Exova) and ALS Pharmaceutical, among 26 companies covered in total.
Which regions and countries are covered for Pharmaceutical Testing?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Pharmaceutical Testing market report?
The report is intended for manufacturers and solution providers, distributors and end users in CRO, CMO and CDMO and Finished Drugs and Environment, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Pharmaceutical Testing market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.